Research map: Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 − metastatic breast cancer: a single-institution experience

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. MSA U-Net: a multi-scale attention-enhanced network for automatic segmentation of uterine lymph nodes in MRI images · 2026 · Related
  3. Palbociclib and Letrozole in Advanced Breast Cancer · Richard S. Finn · 2016 · 3063 citations · Cited by this paper
  4. Lessons learned from different prognostic factors analysis in intermediate-risk neuroblastoma: ten years’ experience at a tertiary center · 2025 · Related
  5. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer · Gabriel N. Hortobágyi · 2016 · 2067 citations · Cited by this paper
  6. Positive rates of endometrial and cervical cytology in ovarian cancer patients with BRCA1/2 germline pathogenic variants · 2026 · Related
  7. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy · George W. Sledge · 2017 · 1707 citations · Cited by this paper
  8. A case–control study investigating the impact of gradient pressure therapy on chemotherapy-induced peripheral neuropathy symptoms and daily activities in paclitaxel-treated patients · 2025 · Related
  9. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer · Nicholas C. Turner · 2018 · 1319 citations · Cited by this paper
  10. Modulated calcium-sensing receptor (CaSR) expression in human breast cancer provided insights into tumor progression and therapeutic potential · 2026 · Related
  11. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer · Dennis J. Slamon · 2019 · 874 citations · Cited by this paper
  12. Global burden of multiple myeloma(1990–2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization · 2026 · Related
  13. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis · Mario Giuliano · 2019 · 195 citations · Cited by this paper
  14. Overcoming barriers: mechanisms and strategies of nanoparticles in overcoming the blood-brain barrier and drug resistance in glioblastomas · 2026 · Related
  15. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions · Laura M. Spring · 2019 · 175 citations · Cited by this paper
  16. The additive value of 3D automated breast ultrasound and contrast enhanced spectral mammography in the assessment of suspicious breast lesions · 2026 · Related
  17. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice · Angela M. DeMichele · 2021 · 133 citations · Cited by this paper
  18. Metabolic and nutritional impact of gastrectomy and perioperative treatment in gastric cancer: a prospective cohort study · 2026 · Related
  19. The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements · Chirag Shah · 2020 · 23 citations · Cited by this paper
  20. Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma · 2026 · Related
  21. Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR ‐positive/ HER2 ‐negative metastatic breast cancer with real‐world data from the OPAL registry · Marc Thill · 2024 · 23 citations · Cited by this paper
  22. Genomic characterisation of cervical cancer and human papillomavirus: new opportunities for precision medicine · Silvia Franceschi · 2021 · 11 citations · Cited by this paper
  23. Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+/HER-2 breast cancer patients treated with CDK4/6 inhibitors · Omar Badran · 2025 · 10 citations · Cited by this paper
  24. Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer – A systematic review and meta-analysis · Yee Yin Hoo · 2025 · 4 citations · Cited by this paper
  25. Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China · Binliang Liu · 2026 · 2 citations · Cited by this paper
  26. Untitled · Cited by this paper

Source: OpenAlex (CC0)